Discover how researchers engineered a BCR-ABL-activated caspase that selectively eliminates leukemic cells while sparing healthy ones.
Exploring CD19-TRAIL fusion protein, a targeted immunotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with promising preclinical results.